CAMBRIDGE, Mass., January 22, 2024 – Casma Therapeutics, Inc., a biotechnology company engaging the autophagy/lysosomal system to provide innovative new medicines, today announced that Leon Murphy, Ph.D., Chief Scientific Officer, will present at the joint Keystone Meeting for Proximity Based Therapeutics and Targeted Protein Degradation in the section of “Emerging Proximity Biology for Target Degradation.” The title of Dr. Murphy’s talk is “Drugging the Autophagy-Lysosomal Pathway.” The presentation will take place on Monday, January 22, 2024. Dr. Murphy will also chair a session entitled “Strategies and Targets for Therapeutics in the Ubiquitin Proteasome System” on Tuesday, January 23, 2024.
About Casma Therapeutics
Casma Therapeutics is developing novel cellular degradation approaches based on the autophagy pathway to initiate new target areas for drug discovery and development that will profoundly impact the lives of patients. Autophagy is a conserved cellular process that contributes to overall cellular homeostasis. The autophagy machinery focuses on larger and more complex disease targets, such as organelles, protein aggregates, and large signaling complexes, and directs these targets to the lysosome for elimination. Through selective degradation of disease targets, Casma expects to arrest or reverse the progression of disease in multiple oncology, inflammation, neurodegeneration, and metabolic disorders.
Contact for Investors and Media
Courteney Backstrom
Casma Therapeutics, Inc.
cbackstrom@casmatx.com
Back to news & media
